Wu Minhong, Zhou Yan, Chen Qingsheng, Yu Zhiling, Gu Hongyong, Lin Pengxiu, Li Yanling, Liu Cailing
Department of Urology, Yichun People's Hospital, Yichun, China.
Department of Nursing, Wanzai County Traditional Chinese Medicine Hospital, Yichun, China.
Front Oncol. 2022 Apr 11;12:879803. doi: 10.3389/fonc.2022.879803. eCollection 2022.
To investigate the potential prognostic role of C-reactive protein to albumin ratio (CAR) in patients with urinary cancers, including renal cell carcinoma (RCC), bladder cancer (BC), and prostate cancer (PC).
We searched and screened literatures with PubMed, Embase, Cochrane Library, and Web of Science in January 2022. We applied combined hazard ratios (HRs) and 95% confidence intervals (CIs) to assess the associations.
Thirteen studies including 2,941 cases were analyzed in our study. Merged results indicated that highly pretreated CAR was associated with inferior overall survival (HR 2.21, 95% CI 1.86-2.62, p < 0.001) and progression-free survival (HR 1.85, 95% CI 1.36-2.52, p < 0.001) for urinary cancers. In a subgroup analysis of OS by tumor type, CAR can be a predictor in RCC (HR 2.10, 95% CI 1.72-2.56), BC (HR 3.35, 95% CI 1.94-5.80), and PC (HR 2.20, 95% CI 1.43-3.37). In a subgroup analysis of PFS by tumor type, CAR can be a predictor in BC (HR 1.76, 95% CI 1.03-3.02), and RCC (HR 1.90, 95% CI 1.25-2.89). The reliability and robustness of results were confirmed.
High pretreated CAR was effective predictor of poor survival in patients with urinary cancers and can act as prognostic factor for these cases.
PROSPERO (CRD42022306414).
探讨C反应蛋白与白蛋白比值(CAR)在尿路上皮癌患者(包括肾细胞癌(RCC)、膀胱癌(BC)和前列腺癌(PC))中的潜在预后作用。
我们于2022年1月在PubMed、Embase、Cochrane图书馆和科学网中检索并筛选文献。我们应用合并风险比(HRs)和95%置信区间(CIs)来评估相关性。
我们的研究分析了13项研究,共2941例病例。合并结果表明,预处理后CAR水平较高与尿路上皮癌患者较差的总生存期(HR 2.21,95% CI 1.86 - 2.62,p < 0.001)和无进展生存期(HR 1.85,95% CI 1.36 - 2.52,p < 0.001)相关。在按肿瘤类型进行的总生存期亚组分析中,CAR可作为RCC(HR 2.10,95% CI 1.72 - 2.56)、BC(HR 3.35,95% CI 1.94 - 5.80)和PC(HR 2.20,95% CI 1.43 - 3.37)的预测指标。在按肿瘤类型进行的无进展生存期亚组分析中,CAR可作为BC(HR 1.76,95% CI 1.03 - 3.02)和RCC(HR 1.90,95% CI 1.25 - 2.89)的预测指标。结果的可靠性和稳健性得到了证实。
预处理后CAR水平较高是尿路上皮癌患者生存不良的有效预测指标,可作为这些病例的预后因素。
PROSPERO(CRD42022306414)。